Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Plain-language summary
This trial is testing Durvalumab for patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial is available at 4 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Durvalumab (BIOLOGICAL): Given IV | Laboratory Biomarker Analysis (OTHER): Correlative studies | Lenalidomide (DRUG): Given PO
Durvalumab, Laboratory Biomarker Analysis, Lenalidomide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details